Filing summary
Issuer and period: The supplied filing is Stellar Biotechnologies, Inc.’s unaudited Form 10-Q for the quarter and six months ended March 31, 2016 (fiscal Q2). This does not match the request metadata naming Edesa Biotech, Inc. The financial information below is for Stellar Biotechnologies, not Edesa.
Business context
Stellar develops, manufactures, and commercializes Keyhole Limpet Hemocyanin (KLH) for biotechnology, pharmaceutical, academic, and clinical research customers. The company reported under U.S. GAAP, in U.S. dollars. Share amounts and prices reflect a 1-for-10 reverse split effective September 2, 2015.
Financial performance
| Metric | Three months ended March 31, 2016 | Six months ended March 31, 2016 |
|---|---|---|
| Revenue | $326,335 | $814,495 |
| Operating expenses | $1,422,278 | $3,217,792 |
| Net loss | $861,010 | $2,490,813 |
| Loss per basic and diluted share | $0.10 | $0.30 |
| Cash used in operating activities | Not separately provided | $2,247,526 |
- Six-month revenue increased from $400,288 in the comparative statement to $814,495, driven by higher product sales; product sales were $782,495 versus $295,288. Contract services revenue declined to $32,000 from $105,000.
- Six-month net loss widened from $1,769,641. The filing attributes much of the year-over-year difference to noncash warrant fair-value effects: a $211,956 loss in 2016 versus a $1,201,332 gain in 2015. Foreign exchange moved to a $117,636 gain from a $468,658 loss.
- Costs of sales and contract services rose to $580,964 from $339,040; R&D fell to $597,911 from $700,405 as focus shifted toward manufacturing; general and administrative expense increased to $1,874,755 from $1,727,834.
- The filing does not present a standalone gross margin. Revenue less costs of sales and contract services was $233,531 for the six months; this excludes separately reported aquaculture costs and other expenses.
Financial position and liquidity
- At March 31, 2016, cash and cash equivalents were $5,961,727, short-term investments were $1,999,162, and working capital was $8,099,383. Total assets were $9,428,738.
- Current liabilities were $616,097, including $442,764 of accounts payable and accrued liabilities and $173,333 of deferred revenue. No debt balance is reported in the presented balance sheet.
- Cash increased by $2,006,224 over the six months, despite operating cash use, principally reflecting $2,752,767 of investing cash inflow and $1,368,260 from warrant exercises. Short-term investments declined by $3,016,009.
- Capital expenditures were $263,242 in the six-month period. The company issued 464,000 shares through warrant exercises; 8,448,758 shares were outstanding at March 31 and May 5, 2016.
Outlook, risks, and notable items
- Management said available resources were expected to support operations at the current level for at least 12 months and to cover anticipated obligations and R&D. It also expected continued losses, said additional capital may be needed, and disclosed that no new financing commitment had been secured.
- Revenue concentration was high: 90% of six-month product sales and contract-services revenue came from five customers; 80% of receivables were due from two customers. Europe represented 45% of revenue, Asia 39%, and the U.S. 16%.
- Commitments included approximately $381,000 for contract research organizations and consultants, estimated additional contractor obligations of about $5,000, and $537,000 of future minimum lease payments. A KLH-related license includes up to $6.02 million of development/financing milestones and $57.025 million of sales milestones, contingent on achieving specified targets.
- The company voluntarily delisted from the TSX Venture Exchange effective April 8, 2016; its shares were listed on Nasdaq. Management reported disclosure controls were effective and no material change in internal control during the quarter. It reported no material legal proceedings outside the ordinary course and no material changes to previously disclosed risk factors.
Important facts to verify
- Confirm the intended issuer: the request names Edesa Biotech, but the supplied 10-Q identifies Stellar Biotechnologies, Inc.
- Reconcile the comparative six-month revenue: the statements show $400,288 for 2015, while MD&A states $400,228.
- Review customer concentration, cash runway assumptions, and whether additional financing will be required, given recurring losses and operating cash use.
- Assess the contingent license milestones and contractual commitments, and distinguish them from current recorded liabilities.